Skip to content
DataLookout
Menu

HYRISSNCT05633771

Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

StatusActive, Not Recruiting
PhaseNot specified
SponsorSandoz
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 10 versions: 7 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Study completion pushed from Dec 2026 to Mar 2027
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 8 to 51
    v9
  3. Minor Secondary endpoints: details revised at 1 of 9 entriesv8
  4. Minor Study sites: 1 to 8v6
  5. Notable Eligibility criteria expanded, about 37 words
    • Study completion date: Dec 15, 2025 to Dec 2026
    • Secondary endpoints: details revised at 1 of 9 entries
    v5
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 28, 2023 to Feb 16, 2023
    v3
  2. Notable Start date: Dec 15, 2022 to Feb 28, 2023
    • Primary and study completion dates: Nov 2, 2026 to Dec 15, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of patients who remain on Hyrimoz® at 6 months after treatment initiation
Timeframe: Up to 6 months

Secondary (9)

Percentage of patients who discontinue Hyrimoz
Percentage of patients with high level of treatment satisfaction using TSQM-9 questionnaire
Percentage of patients with high level of treatment adherence using adapted CQR5 questionnaire
Percentage of patients with the perception of a high level of disease activity using VAS scale
Percentage of patients with a good perception about biosimilars using VAS scale
Show 4 moreShow less
Percentage of patients in remission
Crohn's disease activity measurement: Harvey Bradshaw Index [HBI]
Ulcerative colitis activity measurement: partial Mayo calculation score
Pattern of Hyrimoz® utilization

Arms and interventions

Hyrimoz

Patients prescribed with Hyrimoz

Other: Hyrimoz

Sites

51 sites in 2 countries

France 38, Belgium 13